Dr. West on 4 Important Upcoming Clinical Trial Results

H. Jack West, MD
Published: Thursday, Jul 28, 2011

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses the anticipated results of 4 lung cancer clinical trials.
  1. FORIS-M trial examining the single agent use of talactoferrin in previously treated patients with non-small cell lung cancer (NSCLC).
  2. ECOG 1505 phase III trial looking at adjuvant chemotherapy with or without bevacizumab in completely resected NSCLC.
  3. RADIANT trial examining adjuvant erlotinib for EGFR-positive NSCLC patients, noteworthy because of its isolation of the EGFR mutation.
  4. The evaluation of the recombinant MAGE-A3 vaccine platform as adjuvant therapy in MAGE-A3-Positive NSCLC in addition to or instead of standard chemotherapy.
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses the anticipated results of 4 lung cancer clinical trials.
  1. FORIS-M trial examining the single agent use of talactoferrin in previously treated patients with non-small cell lung cancer (NSCLC).
  2. ECOG 1505 phase III trial looking at adjuvant chemotherapy with or without bevacizumab in completely resected NSCLC.
  3. RADIANT trial examining adjuvant erlotinib for EGFR-positive NSCLC patients, noteworthy because of its isolation of the EGFR mutation.
  4. The evaluation of the recombinant MAGE-A3 vaccine platform as adjuvant therapy in MAGE-A3-Positive NSCLC in addition to or instead of standard chemotherapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x